Neuropeptide • Discovered 1977

DSIP: Delta Sleep-Inducing Peptide

Last updated: March 2026

DSIP is a 9-amino acid neuropeptide first isolated from rabbit brain during induced sleep. It promotes slow-wave delta sleep — the deepest, most restorative phase — while modulating stress response, circadian rhythm, and potentially pain perception.

0
Amino Acids
in Sequence
0
Year
Discovered
0
Typical Dose
(mcg)

What Is DSIP?

A natural sleep-regulatory peptide that was accidentally discovered during sleep research nearly 50 years ago.

In 1977, Swiss scientists Schoenenberger and Monnier isolated a 9-amino acid peptide from the cerebral venous blood of rabbits during electrically induced slow-wave sleep. The sequence — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — was named Delta Sleep-Inducing Peptide (DSIP) for its ability to promote deep delta-wave sleep patterns.

🧬
Amino Acid Sequence

DSIP is a nonapeptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (molecular weight ~848 Da). It is naturally produced in the hypothalamus and found in circulation during sleep states.

🌙
Sleep-Phase Specificity

DSIP specifically promotes Stage 3/4 slow-wave sleep (delta sleep) — the phase responsible for physical restoration, growth hormone release, memory consolidation, and immune function.

🧠
Hypothalamic Origin

Endogenous DSIP is synthesized in the hypothalamus, the brain region that regulates circadian rhythm, body temperature, hunger, and the sleep-wake cycle.

🌍
Cross-Species Presence

DSIP has been identified in mammals, birds, and invertebrates — suggesting it is an evolutionarily conserved sleep-regulatory molecule with fundamental biological importance.

How DSIP Works

DSIP acts through multiple neurochemical pathways — not a single receptor mechanism — which explains its diverse effects on sleep, stress, and pain.

🌊
Delta Wave Promotion

DSIP promotes slow-wave (0.5-4 Hz) EEG patterns during sleep. Delta waves are associated with the deepest non-REM sleep stage, when the body releases growth hormone and performs tissue repair.

Circadian Modulation

DSIP appears to help entrain circadian rhythm and normalize disturbed sleep-wake cycles. It may influence suprachiasmatic nucleus activity — the brain's master clock.

🔗
GABA System Interaction

DSIP modulates GABAergic transmission — the primary inhibitory neurotransmitter system. Unlike benzodiazepines, it enhances natural sleep architecture rather than forcing sedation.

💊
Opioid Pathway Modulation

DSIP interacts with endogenous opioid systems, which may explain its potential analgesic (pain-reducing) properties observed in some animal studies.

😰
Stress-Protective Effects

DSIP normalizes cortisol levels under stress conditions. Animal studies show it can prevent stress-induced pathology and improve resilience to acute stressors.

🛡️
Antioxidant Properties

DSIP exhibits free radical scavenging activity in vitro. This may contribute to its neuroprotective potential, though human relevance remains to be established.

What the Research Shows

DSIP has been studied for nearly 50 years, but most data comes from animal models and small human observational studies.

⚠️ Limited Human Clinical Data

Despite decades of research, DSIP lacks large-scale randomized controlled trials in humans. Most findings come from animal studies, in vitro research, and small open-label human studies. Effects observed in rodents may not translate to humans.

Sleep Research

Sleep Onset Improvement
Reduced time to fall asleep in human observational studies (chronic insomnia)
Moderate
Sleep Quality Enhancement
Improved subjective sleep quality and morning refreshment (observational)
Moderate
Disturbed Sleep Normalization
Restoration of normal sleep patterns in sleep-disordered subjects
Promising

Other Research Areas

Withdrawal Support (Opioid/Alcohol)
Reduced withdrawal symptoms in substance-dependent subjects (small studies)
Preliminary
Analgesic (Pain-Reducing) Effects
Increased pain threshold in animal models via opioid pathway modulation
Preclinical
Stress Cortisol Normalization
Prevented stress-induced cortisol elevation in animal models
Animal Data
Neuroprotective Potential
Antioxidant activity and cell protection in vitro models
In Vitro

Typical DSIP Protocols

Common research protocols based on published studies and reported user experience. Not prescriptive medical advice.

💉 Standard DSIP Protocol
Dose Range
100-300 mcg
Administration
SubQ or Intranasal
Timing
30-60 min before bed
Cycle
2-4 weeks on / 2 weeks off

Starting dose: Begin at 100 mcg to assess individual response. Some individuals are more sensitive to DSIP's effects. Increase to 200-300 mcg only if needed after 3-5 days.

Why cycle? While tolerance data is limited, cycling is generally recommended for peptides affecting neurological pathways. The 2-4 week on / 2 week off pattern is based on common practice, not clinical trials.

🔗 DSIP + Selank Stack (Complementary Pathways)
DSIP
Evening / Before Bed
+
Selank
Morning / Daytime

DSIP optimizes sleep architecture while Selank provides daytime anxiolytic support via GABA modulation. They work through different pathways and are commonly used together — DSIP for restorative sleep, Selank for calm, focused wakefulness.

⚠️ What NOT to Combine

Avoid combining DSIP with other sleep-inducing compounds (benzodiazepines, Z-drugs, high-dose melatonin, alcohol) without physician guidance. Stacking multiple sedative-pathway compounds increases risk of excessive sedation and respiratory depression.

Safety Considerations

DSIP appears well-tolerated in published studies, but long-term human safety data is limited.

Generally Well-Tolerated: No significant adverse effects have been consistently reported in published DSIP studies. It does not appear to cause next-day grogginess ("hangover effect") seen with many sleep medications.
💉
Injection Site Reactions: As with any peptide, subcutaneous injection may cause temporary redness, swelling, or irritation at the injection site. Proper sterile technique minimizes this risk.
🧪
No Established Dependence: Unlike benzodiazepines and Z-drugs, DSIP has not been associated with physical dependence or withdrawal syndromes in available literature. However, this has not been rigorously studied.
Half-Life Uncertainty: DSIP's pharmacokinetic profile in humans is not well-characterized. Some sources suggest a short half-life (~15-30 minutes in blood), but effects on sleep persist longer, suggesting tissue/receptor-level activity.
🚫
Regulatory Status: DSIP is not FDA approved. It is not approved by any major regulatory agency for human therapeutic use. It is sold as a research chemical and is not intended for human consumption.
🤰
Contraindications (Theoretical): Pregnancy, breastfeeding, pediatric use, and concurrent use with CNS depressants should be considered contraindications pending safety data.

Key Study Citations

Study 1 — Original Discovery 1977
Characterization of a delta-electroencephalogram (sleep)-inducing peptide
Schoenenberger GA, Monnier M · Proc Natl Acad Sci USA · 1977
PMID: 266737
Study 2 — Sleep Effects Review
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM · J Neurochem · 1994
PMID: 7798926
Study 3 — Stress-Protective Effects
Stress-limiting effect of delta sleep-inducing peptide
Koplik EV, Sudakov KV · Biull Eksp Biol Med · 1991
PMID: 1878621
Study 4 — Withdrawal Support
Use of delta sleep-inducing peptide in opiate and alcohol withdrawal
Dick P, Grandjean ME, Bhend H · Gen Pharmacol · 1984
PMID: 6090170

Key Takeaways

✅ What We Know
  • 9-amino acid neuropeptide discovered 1977
  • Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
  • Naturally produced in the hypothalamus
  • Promotes slow-wave (delta) sleep — deepest sleep phase
  • Interacts with GABA and opioid systems
  • Stress-protective effects in animal models
  • Potential antioxidant and analgesic properties
  • Generally well-tolerated in available studies
⚠️ What We Don't Know
  • No large Phase 2/3 human clinical trials
  • Precise receptor mechanism still debated
  • Optimal dose for humans not established
  • Long-term safety profile unknown
  • Pharmacokinetics in humans poorly characterized
  • Whether observed effects translate from animals to humans
  • Interactions with other sleep/CNS compounds

🛒 Recommended Products

Sleep optimization and peptide research supplies.

🌙 Magnesium Glycinate Sleep-supporting mineral form 👓 Blue Light Glasses Evening screen protection 😴 Contoured Sleep Mask Total light blocking 💉 Insulin Syringes 29G For research peptide admin 🧴 Bacteriostatic Water Peptide reconstitution 🧪 Glycine Powder Sleep quality amino acid

Affiliate links help support MeetPeptide at no extra cost to you.

🔗 Related Resources

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚠️ Important Disclaimer

This page is for educational and informational purposes only. DSIP (Delta Sleep-Inducing Peptide) is a research peptide not approved by the FDA or any regulatory body for human therapeutic use. Most published research consists of animal studies and small human observational studies. No large human clinical trials have been completed. The safety and efficacy of DSIP in humans has not been established. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.